These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12412532)

  • 21. Oxaliplatin in the treatment of colorectal cancer.
    Kim GP; Erlichman C
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
    Grothey A; Sargent DJ
    J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule.
    Meyer L; Zuberbier T; Worm M; Oettle H; Riess H
    J Clin Oncol; 2002 Feb; 20(4):1146-7. PubMed ID: 11844841
    [No Abstract]   [Full Text] [Related]  

  • 24. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid.
    Gedlicka C; Scheithauer W; Schüll B; Kornek GV
    J Clin Oncol; 2002 Aug; 20(15):3359-61. PubMed ID: 12149316
    [No Abstract]   [Full Text] [Related]  

  • 25. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 26. Laryngopharyngeal dysthesia (LPD) in oxaliplatin infusion (OXLP).
    Bahulikar AV; Joshi JN
    J Assoc Physicians India; 2006 Aug; 54():667. PubMed ID: 16941804
    [No Abstract]   [Full Text] [Related]  

  • 27. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 28. Extravasations of oxaliplatin.
    Kretzschmar A; Pink D; Thuss-Patience P; Dörken B; Reichert P; Eckert R
    J Clin Oncol; 2003 Nov; 21(21):4068-9. PubMed ID: 14581435
    [No Abstract]   [Full Text] [Related]  

  • 29. Satraplatin: an orally available platinum analog for the treatment of cancer.
    Choy H
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
    Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
    Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
    Dalzell MD
    Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
    [No Abstract]   [Full Text] [Related]  

  • 32. [Results of a phase-I clinical study of carboplatin--(cyclobutane-1,1-dicarboxylate)diamineplatinum (II)].
    Gorbunova VA
    Vestn Akad Med Nauk SSSR; 1986; (5):45-7. PubMed ID: 3524054
    [No Abstract]   [Full Text] [Related]  

  • 33. Limited activity of carboplatin in malignant lymphoma.
    Danieu L; Warrell RP
    Cancer Treat Rep; 1986 Jul; 70(7):931-2. PubMed ID: 3521851
    [No Abstract]   [Full Text] [Related]  

  • 34. Recombinant IL-11 approved as platelet booster.
    Nat Biotechnol; 1998 Jan; 16(1):7. PubMed ID: 9447578
    [No Abstract]   [Full Text] [Related]  

  • 35. [Application of eloxatin for the treatment of widespread colorectal cancer].
    Miasoiedov DV; Ievtushenko OI; Iugrinov OH
    Klin Khir; 2001 Dec; (12):41-3. PubMed ID: 11944274
    [No Abstract]   [Full Text] [Related]  

  • 36. Oxaliplatin-induced Evan's syndrome.
    Earle CC; Chen WY; Ryan DP; Mayer RJ
    Br J Cancer; 2001 Feb; 84(3):441. PubMed ID: 11161414
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity?
    Sebagh M; Plasse M; Lévi F; Adam R
    Ann Oncol; 2005 Feb; 16(2):331; author reply 332-3. PubMed ID: 15668292
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug approval triggers debate on future direction for cancer treatments.
    Frantz S
    Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324
    [No Abstract]   [Full Text] [Related]  

  • 39. Serious delayed hypersensitivity reaction to oxaliplatin.
    de Vries RS; Mattijssen EJ; van Sorge AA
    Ann Oncol; 2006 Nov; 17(11):1723-4. PubMed ID: 16757568
    [No Abstract]   [Full Text] [Related]  

  • 40. [Iproplatin--advantages and disadvantages of a new platinum cytostatic agent].
    Hejl J; Hejlová N
    Cas Lek Cesk; 1988 Apr; 127(15):467-70. PubMed ID: 3378253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.